Gregory Gordon


Vice President,
Clinical

Dr. Gregory Gordon joined Rhythm in September 2018.  As our Vice President of Clinical, he is responsible for overseeing our clinical trials and leading the Clinical Operations and Clinical Development teams. Prior to joining us, Gregory served as Head of U.S. Medical at TiGenix where he was responsible for the U.S. clinical development of Alofisel, the first allogenic stem cell therapy to receive central marketing authorization in Europe. Gregory oversaw the U.S. development program, preparing for approval for its primary indication of complex perianal fistulas of Crohn’s disease, as well as evaluating potential new indications for label extension, until the purchase of TiGenix by Takeda Pharmaceuticals in 2018. Prior to that, Gregory was the Global Clinical Affairs Lead for Gastrointestinal Health at Nestle Health Science, where he oversaw clinical development efforts to treat Inflammatory Bowel Disease. The team’s development strategy focused on building multiple external partnerships to create a range of potentially complementary treatment pathways, including microbiome and phosphatidylcholine-based therapeutics and nutritional supplementation. Gregory has held positions at a number of biopharmaceutical companies, including Stealth BioTherapeutics and Ironwood Pharmaceuticals.  He began his medical career as a primary care physician in the Boston area.  He earned a J.D. from Columbia University Law School, an M.D. from Stony Brook University, and completed his Internal Medicine Residency at Lenox Hill Hospital in New York City.